2m 2m 2m 2m 2m 2m 2m
PLUS THERPEUTCS (PSTV)
NASDAQ
$4.01-$0.07 (-1.76%)
Price as of Jun 23, 2026 7:55 PM EDT- $27.4MMarket Cap
- -12.73%1-Year Change
- BiotechnologyIndustry
PLUS THERPEUTCS (PSTV)
$4.01-$0.07 (-1.76%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 5.2M N/A | N/A N/A | 9.8M +2,214.39% | 424,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 5.2M N/A | 0 -100.00% | 9.8M +2,214.39% | 424,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -8.4M -20.80% | -10.6M +9.18% | -9.7M -0.08% | -9.7M +74.02% | |
Depreciation and Amortization Expense | 445,000 -38.45% | 723,000 +15.13% | 628,000 +1.45% | 619,000 +56.71% | |
Total Operating Expenses | 20.5M -0.04% | 20.5M +12.53% | 18.2M -8.54% | 19.9M +59.59% | |
Operating Profit | -15.3M +4.10% | -14.7M +10.31% | -13.3M -32.42% | -19.7M +57.80% | |
Interest Income | 116,000 -57.51% | 273,000 -31.75% | 400,000 +172.11% | 147,000 +673.68% | |
Interest Expense | N/A N/A | N/A N/A | -395,000 -44.44% | -711,000 -23.71% | |
Interest Income and Expense and Net | 116,000 -57.51% | 273,000 +5,360.00% | 5,000 +100.89% | -564,000 -38.23% | |
Total Nonoperating Income and Expense | -7.1M -512.81% | 1.7M +34,240.00% | 5,000 +100.89% | -563,000 -37.93% | |
Income before Taxes | -15.3M +4.10% | -14.7M +10.31% | -13.3M -32.42% | -19.7M +57.80% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | -22.4M +72.49% | -13.0M -2.54% | -13.3M -34.32% | -20.3M +51.32% | |
Net Income from Continuing Operations Applicable to Common | -22.4M +72.49% | -13.0M -2.54% | -13.3M -34.32% | -20.3M +51.32% | |
Basic EPS and Net Income | -0.29 -85.13% | -1.95 -54.01% | -4.24 +450.65% | -0.77 -30.63% | |
Diluted EPS and Net Income | -0.29 -87.61% | -2.34 -44.81% | -4.24 +450.65% | -0.77 -30.63% | |
Basic Weighted Average Shares | 77.8M +1,071.71% | 6.6M +111.41% | 3.1M -88.04% | 26.3M +117.18% | |
Diluted Weighted Average Shares | 77.8M +910.35% | 7.7M +145.18% | 3.1M -88.04% | 26.3M +117.18% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 4.3M +5,500.00% | 76,000 -99.11% | 8.6M -52.79% | 18.1M -1.52% | |
Short-Term Investments | 4.4M +23.40% | 3.5M N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 8.6M +138.82% | 3.6M -57.84% | 8.6M -52.79% | 18.1M -1.52% | |
Total Current Assets | 15.2M +188.46% | 5.3M -46.52% | 9.8M -54.93% | 21.8M +10.61% | |
Accumulated Depreciation | 3.3M +6.21% | 3.1M +23.82% | 2.5M +29.39% | 2.0M +38.52% | |
Property and Plant and Equipment and Net | 257,000 -42.63% | 448,000 -50.55% | 906,000 -31.57% | 1.3M -10.36% | |
Total Long-Term Assets | 123,000 +925.00% | 12,000 -62.50% | 32,000 +166.67% | 12,000 -25.00% | |
Total Assets | 16.3M +146.12% | 6.6M -41.75% | 11.4M -52.29% | 23.9M +8.58% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 750,000 -89.68% | 7.3M +82.80% | 4.0M +147.26% | 1.6M 0.00% | |
Total Current Liabilities | 12.3M -20.82% | 15.6M +44.97% | 10.7M -9.49% | 11.9M +101.91% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 3.8M 0.00% | 3.8M -24.36% | |
Total Long-Term Liabilities | 15,000 -99.23% | 2.0M -66.26% | 5.8M +4.02% | 5.6M +5.61% | |
Total Liabilities | 12.3M -20.88% | 15.6M +22.35% | 12.7M -26.90% | 17.4M +56.32% | |
Retained Earnings | -515.9M +4.54% | -493.5M +2.70% | -480.5M +2.85% | -467.2M +4.54% | |
Total Stockholders Equity | 4.0M +144.65% | -8.9M +563.87% | -1.3M -120.92% | 6.4M -40.52% | |
Total Shares Outstanding | 138.7M +2,251.90% | 5.9M +30.37% | 4.5M -86.54% | 33.6M +116.64% | |
Cash Flow | |||||
Cash from Operating Activities | -20.8M +96.84% | -10.6M -17.87% | -12.9M -0.93% | -13.0M +26.19% | |
Capital Expenditures | 67,000 -54.11% | 146,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -854,000 -79.23% | -4.1M +2,469.38% | -160,000 -78.92% | -759,000 +825.61% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 30.3M +389.91% | 6.2M +79.59% | 3.4M -74.39% | 13.5M -34.12% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -293.46% N/A | N/A N/A | -135.75% -97.08% | -4,649.06% N/A | |
Return on Assets | -195.02% +35.40% | -144.03% +90.67% | -75.54% -14.59% | -88.44% +12.50% | |
Return on Equity | 903.94% +258.60% | 252.07% +148.24% | -522.50% +122.67% | -234.65% +21.42% | |
Revenue Growth | N/A N/A | N/A N/A | 2,214.39% N/A | N/A N/A | |
Current Ratio | 1.23 +264.25% | 0.34 -63.11% | 0.92 -50.20% | 1.84 -45.22% | |
Cash Ratio | 0.35 +6,953.06% | 0.005 -99.39% | 0.80 -47.84% | 1.53 -51.23% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | -5.76 -788.04% | 0.84 +37.13% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.68 +201.59% | 0.23 -24.89% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow